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Abstract
Background: HIV infection causes a qualitative and quantitative loss of CD4+ T cell immunity. The institution of
anti-retroviral therapy (ART) restores CD4+ T cell responses to many pathogens, but HIV-specific responses remain
deficient. Similarly, therapeutic immunization with HIV antigens of chronically infected, ART treated subjects results
in poor induction of HIV-specific CD4 responses. In this study, we used a macaque model of ART treatment during
chronic infection to study the virologic consequences of SIV antigen stimulation in lymph nodes early after
immunization. Rhesus CMV (RhCMV) seropositive, Mamu A*01 positive rhesus macaques were chronically infected
with SIVmac251 and treated with ART. The immune and viral responses to SIV gag and RhCMV pp65 antigen
immunization in draining lymph nodes and peripheral blood were analyzed. Animals were immunized on
contralateral sides with SIV gag and RhCMV pp65 encoding plasmids, which allowed lymph nodes draining each
antigen to be obtained at the same time from the same animal for direct comparison.
Results: We observed that both SIV and RhCMV immunizations stimulated transient antigen-specific T cell
responses in draining lymph nodes. The RhCMV-specific responses were potent and sustained (50 days post-
immunization) in the periphery, while the SIV-specific responses were transient and extinguished quickly. The SIV
antigen stimulation selectively induced transient SIV replication in draining lymph nodes.
Conclusions: The data are consistent with a model whereby viral replication in response to SIV antigen stimulation
limits the generation of SIV antigen-specific responses and suggests a potential mechanism for the early loss and
poor HIV-specific CD4+ T cell response observed in HIV-infected individuals.
Background
CD4+ T cells play a central role in maintaining effective
cellular and humoral immune responses by providing
help to CD8+ T cells, B cells and innate effectors. The
protective role of CD4+ T cell responses in HIV-1 infec-
tion has been suggested in previous studies [1,2]. How-
ever, HIV-1 infection results in the progressive loss of
CD4+ T cell responses, which is characterized as both a
decline in the number of CD4+ T cells and a loss of the
functional activity of cells with certain antigenic
specificities [3-6]. Although the institution of anti-retro-
viral therapy (ART) causes viral suppression and recov-
ery of CD4+ T cell response to some common
pathogens, HIV-specific CD4 response remains deficient
[7,8]. Similarly, immunization of chronically infected,
ART treated patients with HIV antigens does not result
in the generation of significant HIV-specific CD4+ T cell
responses, suggesting that HIV-specific CD4+ T cells
are dysfunctional or preferentially depleted in infection
and fail to recover [9-11]. The mechanisms for the fail-
ure of HIV antigen immunization to induce HIV-speci-
fic CD4+ response are not fully clear [12].
During an immune response, antigen-presenting cells
(APC) activate CD4+ T cells to specific antigen
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specificities in lymphoid tissue. However, in HIV-1
infection, lymphoid tissue also represents an important
site for viral replication, and the interaction between
APC and CD4+ T cells may enhance viral replication by
multiple mechanisms (reviewed in [13]). It has been
shown that even in the setting of potent regimens of
ART, a very low level of viral replication could still be
detected [14-16], which may be derived from DC
mediated activation of latent virus in memory CD4+ T
cells, homeostatic regulation of memory populations, or
other long-lived reservoirs [17]. Given that HIV-specific
CD4+ memory T cells are preferentially infected by
HIV, carrying more viral DNA than total memory cells
[18], we were interested in determining if activation of
HIV-specific CD4+ T cells results in viral replication in
lymphoid tissue.
We used a rhesus macaque model of ART treatment
during chronic infection to study the effects of SIV anti-
gen stimulation in lymph nodes (LNs) compared to a
control immunogen on viral replication early after
immunization. Mamu A*01+ rhesus macaques were
infected with SIVmac251 and after 4 months treated
with ART resulting in viral suppression and immune
reconstitution. The macaques were also rhesus CMV
(RhCMV) seropositive and immunized with an RhCMV
immunogen as a control antigen stimulation. Animals
were immunized on the left side (both arms and legs)
with an SIV gag-encoding expression plasmid and on
the right side (both arms and legs) with a RhCMV
pp65-encoding expression plasmid, which allowed drain-
ing LNs for each antigen to be obtained from the same
animal at the same time, allowing for a direct compari-
son of the effect of SIV and RhCMV antigen stimulation
on viral replication.
Results
Infection and immunization of rhesus macaques
All animals used in this study (FH40, DD05, and CT64)
were Mamu A*01 positive to reduce MHC variation in
disease course and T cell responses and were naturally
infected with RhCMV. The study was designed to infect
animals (1000 TCID50 of SIVmac251 by intravenous
injection) and allow them to reach steady state viral
loads (4 months) followed by ART treatment (PMPA
and D4T) for 5.5 months. Animals were then immu-
nized with plasmids encoding SIV gag or RhCMV pp65
in both arms and legs. Two LN biopsies draining either
SIV gag or RhCMV pp65 injections from the same ani-
mal at the same time were obtained on the indicated
days (D3: FH40 Inguinal; D5: DD05 Inguinal, D7: CT64
Inguinal; D9: FH40 Axillary; D11: DD05 Axillary, D14:
CT64 Axillary) (Figure 1). Immunizations used expres-
sion plasmids previously used as vaccines that were
demonstrated to induce potent T cell responses in unin-
fected rhesus macaques [19-25]. Serum and PBMCs
were obtained every 2 to 3 weeks throughout the
experiment.
ART suppresses viral replication with recovery of
peripheral CD4+ T cell counts
SIV infection was established in all three animals with
kinetics typical of primary infection in naïve rhesus
macaques (Figure 2A) [26,27]. Introduction of ART 4
months post infection, when set point viral loads had
been established, efficiently suppressed viral replication
to undetectable levels. One macaque demonstrated occa-
sional blips in viral load that returned to undetectable
levels by the subsequent measurement without any
change in therapy (Figure 2A). Absolute CD4+ T cell
Figure 1 Experimental protocol for infection and immunization of rhesus macaques. Mamu A*01 rhesus macaques naturally infected with
RhCMV were intravenously inoculated with SIVmac251 followed by ART treatment (DT4 and PMPA) from days 119 post infection through the
end of experiment. On days 286 or 290 post infection, monkeys received immunizations with SIV gag encoding DNA i.m. (2 mg per injection), in
the left arm and left leg, and immunizations with RhCMV pp65 encoding DNA i.m. (2 mg per injection) in the right arm and leg. LNs biopsies
draining either SIV gag or RhCMV pp65 immunization sites from the same animal at the same time were obtained on Day 3 for FH40, Day 5 for
DD05, Day 7 for CT64, Day 9 for FH40, Day 11 for DD05, and Day 14 for CT64. LN biopsies from both sides were also collected from all animals
on Day 60 post immunization. PBMCs were collected pre-immunization and every 2-3 weeks post immunization.
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counts in the peripheral blood demonstrated stabilization
after introduction of ART in all animals with sustained
levels of more than 500 cells/μl (Figure 2B). These find-
ings demonstrate that chronic SIV infection was achieved
and ART successfully suppressed viral replication leading
to partial recovery of peripheral CD4+ T cell counts.
SIV and RhCMV antigen immunization induces antigen-
specific T cell responses in draining LNs
Animals were immunized with SIV gag encoding plas-
mid in the arm and leg on one side and RhCMV pp65
encoding plasmid on the other side at the same time.
LNs, one draining an SIV immunization site and one
draining an RhCMV immunization site, were excised
from each animal at 2 time points (axillary and ingu-
inal) post immunization. LN biopsies from both sides
from all macaques were also collected on day 60-post
immunization. We found that the levels of antigen-
specific responses in day 60 LNs were similar in com-
paring both antigens in both LNs, suggesting that the
effects of immunization on T cell responses in the LNs
were transient and returned to baseline by 60 days
post immunization (Figure 3 and data not shown).
Therefore, this time point was chosen as a baseline for
standardization.
First, we assessed immune activation induced by anti-
gen immunizations in draining LNs to determine
whether the two DNA plasmids were immunogenic. LN
mononuclear cells were analyzed for IFN-g mRNA
expression, a major effector cytokine for adaptive immu-
nity. As shown in Figure 3A, an increase in IFN-g
mRNA expression was detected in LNs draining SIV gag
and RhCMV pp65 on day 3 post immunization, which
was followed by a decline on day 5 to the baseline levels
as observed in day 60 LNs (Figure 3A). The result sug-
gests that both DNA plasmids are immunogenic in the
rhesus macaques used in this study, which is consistent
with previous primate studies where the same DNA
plasmids were used and shown to be immunogenic in
uninfected macaques [19-25].
We then evaluated the antigen-specific T cell responses
in LNs by measuring ex vivo cytokine production of LN
mononuclear cells. Cells were stimulated with either SIV
gag or RhCMV pp65 peptide pools and production of IL-
2, TNF-a and IFN-g in T cells was determined by poly-
chromatic flow cytometry. Flow cytometry plots for cyto-
kine staining are shown (Figure 3B and 3C). We found
that the LN draining SIV gag on day 3, when the immune
activation, as measured by IFN-g mRNA, was the highest,
demonstrated potent gag-specific T cell responses based
on IL-2, TNF-a and IFN-g production (Figure 3B and
3D). In contrast, the day 3 LN draining RhCMV pp65
immunization from the same animal, when stimulated by
gag peptides, demonstrated no significant response (Fig-
ure 3B and 3D). Some multifunctionality of the CD4+ T
cell response was observed with approximately 4%
expressing three cytokines and 28% expressing two. Simi-
larly, the LNs collected on day 5 post immunization were
evaluated for RhCMV-specific T cell responses by stimu-
lating the LN cells with RhCMV-pp65 peptides. A signifi-
cant RhCMV-specific response was induced in the LN
draining the RhCMV pp65 compared to the LN draining
the SIV gag immunization site (Figure 3C and 3E). Drain-
ing LN responses to SIV immunization decreased by day
5 and from day 7 onwards were similar to the levels
observed in day 60-post immunization LNs (Figure 3F
and 3G). Taken together, these data suggest that both
SIV and RhCMV immunization induced transient anti-
gen-specific T cell responses in draining LNs.
Differential SIV- and RhCMV-specific T cell responses in
peripheral blood
Both antigens were immunogenic and induced antigen-
specific T cell responses in draining LNs, we next
Figure 2 Viral loads and peripheral CD4+ T cell counts. Viral
loads and CD4 counts were measured every 2 to 3 weeks
throughout the experiment. (A) Viral RNA in plasma was quantified
by a bDNA signal amplification assay and expressed as viral RNA
copies per ml plasma. ART treatment controlled the viral loads in all
three animals. (B) Peripheral CD4+ T cell counts increased after the
initiation of ART. Macaque blood samples were stained for CD3,
CD4, and CD8 and the number of CD3+, CD4+ T lymphocytes were
determined by flow cytometry and peripheral white blood cell
counts. CD4+ T cell counts are expressed as CD4+ T cells per μl
blood.
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Figure 3 Antigen-specific responses in LNs draining SIV gag and RhCMV pp65 immunization sites. (A) Composite result for IFN-g mRNA
levels in LNs draining SIV gag or RhCMV pp65 immunization sites for each animal on indicated time points. Total RNA from LNMCs was
collected on the indicated days post immunization and subject to real-time PCR for the quantitation of IFN-g mRNA. The results are expressed as
the number of copies of IFN-g mRNA per μg total RNA. Standard deviation of the mean for triplicate analyses for Day 3 LNs draining SIV gag
and RhCMV immunization sites are shown. (B and D) Intracellular cytokine staining (ICS) for SIV gag-specific CD4+ and CD8+ T cell responses in
day 3 LNMCs. Day 3 post immunization LNMCs draining either SIV-gag (top panels, B) or RhCMV-pp65 (bottom panels, B) immunization sites
were stimulated with SIV gag 15-mer overlapping peptide pools and stained for IL-2, TNF-a, and IFN-g. SIV-specific cytokine-producing CD4+ and
CD8+ T cells were analyzed by multi-color flow cytometry. (C and E) Intracellular staining of RhCMV pp65-specific CD4+ and CD8+ T cell
responses in day 5 LNMCs. Day 5 post immunization LNMCs draining either SIV-gag (top panels, C) or RhCMV-pp65 immunizations (bottom
panels, C) were stimulated with RhCMV pp65 15-mer overlapping peptide pools and stained for IL-2, TNF-a, and IFN-g. The composite results for
percent of SIV-specific cytokine producing CD8+ (F) and CD4+ (G) T cells in LNMCs draining SIV gag immunization sites for one macaque at
indicated days post immunization are shown. Cytokine producing T cells in LNMCs without stimulation (background) were subtracted from all
flow analyses.
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analyzed T cell responses induced by immunization in
the peripheral blood. PBMC collected at multiple time
points post immunization were stimulated with SIV gag
or RhCMV pp65 peptide pools and the frequency of
cytokine producing T cells were analyzed by polychro-
matic flow cytometery. We expressed the data as the
percent of CD8+ T cells able to produce any cytokine or
combination of cytokines (IL-2, TNF-a and/or IFN-g)
after subtracting the levels in unstimulated cells. The
average of all animals is shown (Figure 4A). A potent
increase in RhCMV-specific CD8+ T cells was observed
at day 3-post immunization in blood with an average of
1.4% of cells able to produce a cytokine. The RhCMV-
specific response was sustained until day 50 post-immu-
nization. In contrast, SIV-specific CD8+ T cell responses
were transient and extinguished quickly in the blood
with only an increase on day 9 post-immunization
(Figure 4A). Further characterization of the gag and
pp65 responses demonstrated that gag-specific cells had
increased levels of expression of PD1 and contained
both central memory (CD95+, CD28+) and effector
memory (CD95+, CD28-) cells, while the pp65 respond-
ing cells were predominantly effector memory pheno-
type. All animals demonstrated similar kinetics of gag
and pp65 specific responses. PBMCs were stained with
the Mamu A*01 specific gag tetramer, p11C (CTPY-
DINQM). All animals demonstrated a decrease in tetra-
mer positive CD8+ T cells after the initiation of ART,
but levels remained above 1% after 5.5 months of sup-
pressive ART (Figure 4B).
SIV antigen immunization induces transient activation of
viral replication in the draining LN
We next determined whether immunization with SIV or
CMV antigens induced the activation of viral replication
at early, 3 to 7 days, or late, 9 to 14 days, time points.
Total RNAs from LN mononuclear cells (LNMC) drain-
ing either SIV gag or RhCMV pp65 immunization sites
were analyzed by real-time PCR for early and late SIV
RNA transcripts, including doubly spliced (tat), singly-
spliced (vif), and unspliced (gag) RNA [28]. The use of
isolated cells with multiple washes both before and after
cryopreservation removed any extracellular viral RNA
that was present as free or germinal center associated
virions. All comparisons were made between LNs from
the same animal obtained at the same time that differed
only in whether they drained an SIV or a RhCMV
immunization site. We first investigated SIV RNAs in
day 60 LNMCs and found low levels of all 3 transcripts.
Importantly, no difference was observed for each viral
RNA species at this time point in comparing LNMCs
draining SIV and RhCMV immunization sites from the
same animal. Therefore, we used these levels of SIV
RNA as a baseline for the analysis of the effect of anti-
gen stimulation on viral replication for that animal.
Copy numbers of SIV RNA were normalized to GAPDH
RNA, and the results for each time point following
immunization are shown as fold change relative to RNA
collected at 60 days post immunization for that animal
(Figure 5).
Each analysis was performed in the same animal at the
same time point where the only difference was the type
of immunization drained, thereby avoiding the need to
consider confounders present in comparisons between
animals. The effects of antigen-specific stimulation on
SIV replication were first determined by comparing the
levels of SIV doubly spliced RNA in LNMCs draining
SIV gag and RhCMV pp65 immunization. Doubly
spliced RNA copies were significantly increased in the
LNMCs draining the SIV gag immunization compared
to those draining the pp65 immunization on days 3, 5,
Figure 4 SIV- and RhCMV-specific T cell responses in
peripheral blood. (A) PBMCs before and after immunizations were
stimulated with either SIV gag or RhCMV pp65 peptide pools and
stained for IL-2, TNF-a, and IFN-g. The percentages of cytokine-
producing CD8+ T cells were determined by multi-color flow
cytometry. The percent of CD8+ T cells able to make any cytokine is
shown. The average of all animals is shown on the indicated days
post immunization. Error bars are the standard error of the mean, p-
values using the student’s t-test comparing the levels before
immunization (Day 0) to time points post-immunization are shown
as a * indicating a p < 0.05. (B) Measurement of p11c tetramer+,
CD8+ T cells throughout the experiment. The results are expressed
as percent of tetramer+, CD8+ T cells on indicated days post SIV
infection for each animal.
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and 7 (Figure 5A). Singly spliced SIV RNA was
increased in LNMCs draining SIV gag immunizations
on days 5 and 7 (Figure 5B). Similar to the spliced SIV
RNAs, all three monkeys demonstrated a statistically
significant increase in unspliced viral RNA in LNMCs
draining SIV gag immunization compared to RhCMV-
pp65 immunization on days 3, 5, and 7 (Figure 5C). At
the latter time points, viral replication in the LNMCs
draining SIV gag immunizations were not significantly
increased compared to LNMCs draining RhCMV pp65
and by day 14, all viral RNAs from LNMCs draining
both gag and RhCMV decreased towards baseline levels
(Figure 5 A-C). Random effects models were used to
adjust for observations from the same animal, which
demonstrated that on days 3-7, there was a statistically
significant increase in viral replication comparing
LNMCs draining SIV gag to those draining RhCMV
pp65.
We hypothesized that viral replication would occur
soon after immunization and analyzed the early (days 3,
5, and 7) and late (days 9, 11, and 14) time points as
groups. Comparing viral replication in all animals
induced by gag and pp65 immunization in draining
LNMCs at the early time point (days 3 - 7) showed a
significant increase by gag immunization; doubly spliced
(p = 0.0007), singly spliced (p = 0.029), and unspliced (p
= 0.032). These data show that all rhesus macaques
demonstrated significant increases, whether analyzed
singly or as a group, in viral replication in LNMCs
draining SIV gag immunizations. The percent of CD4+
T cells in LNMCs did not differ between LNs draining
SIV gag and RhCMV pp65 immunization sites, suggest-
ing that the increase in viral gene expression was not
due to differential CD4+ T cell migration to LNs drain-
ing gag immunization sites, although we cannot rule out
that a larger fraction of cells that trafficked to the gag
LN were infected.
No increase in viral load was observed in peripheral
blood in response to immunization
We next sought to determine whether this transient
viral replication in LNMCs was observed in peripheral
blood. Viral loads, measured by standard bDNA signal
amplification, in peripheral blood prior to and after anti-
gen immunization in all animals are shown in Table 1.
Except for a transient viral blip in one animal at day 31
post-immunization (270 copies/μl) that returned to
undetectable 3 weeks later, no increase in viral loads
that could be attributed to SIV gag immunization
induced viral replication was detected. The data suggest
that in the setting of potent anti-viral suppression, SIV
antigen immunization activated viral replication was
transient and restricted to draining LNs without spread
to the periphery.
Figure 5 Quantitation of viral RNAs in LNMCs draining
immunization sites. Total RNA extracted from LNMCs draining
either SIV gag or RhCMV pp65 immunization sites, one animal per
time point, were subject to real-time PCR to quantitate SIV doubly
spliced (tat) (A), singly spliced (vif) (B), and unspliced (gag) (C) RNA.
LNMCs draining the RhCMV pp65 immunization site (Gray). LNMCs
draining the SIV gag immunization site (Black). Copy numbers of SIV
RNAs were normalized to macaque GAPDH mRNA, and the results
for each time point following immunization (PI, post immunization)
are shown as fold change relative to RNA analyzed on day 60-post
immunization from the same animal, as no differences between LNs
draining gag or pp65 immunizations were found at this time point.
Error bars are the standard error of the mean of replicate analyses.
Statistical analysis compared viral RNA between LNMCs draining SIV
and CMV immunization sites in the same animal on the same day.
Most measurements were repeated in at least two separate
experiments with identical results.
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Discussion
A biphasic destruction of CD4+ T cells is observed in
HIV infection with a massive loss of CD4+ T cells dur-
ing early infection and a subsequent progressive loss
during the chronic stage of infection [29,30]. Retroviral
suppression by ART results in an increase in peripheral
CD4+ T cell counts and functional reconstitution of
CD4+ T cell responses to many common antigens
[31,32], but HIV-specific CD4+ T cell responses remain
deficient [33]. We studied ART-treated, chronic SIV and
RhCMV infected rhesus macaques and observed; 1) that
both SIV and RhCMV antigen immunizations could
induce immune activation and antigen-specific T cell
responses in draining LNs. 2) In peripheral blood, the
RhCMV-specific response induced by immunization was
potent and sustained, whereas the SIV-specific response
extinguished quickly. 3) We observed that SIV antigen
immunization transiently induced greater levels of SIV
replication in draining LNs of all animals compared to
RhCMV immunization. In this study, the experimental
design of immunizing the same animal with both an
SIV antigen and a non-SIV antigen on collateral sides
allowed us to directly compare the early immune and
viral responses in draining LNs from the same animal at
the same time, making it possible to study the effect of
antigen stimulation in the context of ART-treated,
chronic infection with limited animal numbers. All 3
animals displayed persistent CMV specific T cell
responses for 50 days and demonstrated a weak transi-
ent SIV specific T cell response in peripheral blood.
LNMCs from all animals demonstrated elevated levels
of viral replication in response to SIV antigen immuni-
zation during the first 7 days after immunization. The
data do not prove a causal link between the weak SIV T
cell responses and LN viral replication, but are consis-
tent with a hypothesis that SIV antigens induce viral
replication that leads to depletion or dysfunction of anti-
gen specific cells leading to a reduction in the strength
and longevity of the response.
Pathogenic SIVmac251 infection of rhesus macaques
has been well described as one of the preferred experi-
mental models for studying HIV pathogenesis [34]. In
this study, all rhesus macaques inoculated with SIV-
mac251 were Mamu A*01 positive to control for an
MHC effect on viral immune responses and disease pro-
gression, as well as to aid in the measurement of
immune responses by a Mamu A*01 restricted SIV gag
tetramer. All macaques established primary SIV infec-
tion with typical viral replication dynamics [26,27,35],
and demonstrated responsiveness to ART with rapid
control of viremia (Figure 2A). One animal had occa-
sional blips in viral load that returned to undetectable
without changes in therapy. It has been shown that even
during the most potent regimens of retroviral suppres-
sion, the presence of virus in plasma could be measured
by some ultrasensitive assays [14-16]. We believe the
blips in FH40 are similar to those observed during ther-
apy in humans, which are not associated with acute
infection of cells [36] and believe that this is representa-
tive of a range of low level virus that can be measured
during ART [37]. One study identified that HIV-infected
subjects that developed blips in viral load had higher
instead of lower levels of CD4+ T cell responses to gag
[38]. We do not believe that the macaque with blips in
viral load is responding differently to ART compared to
the animals without measureable blips.
Therapeutic immunization for HIV infection during
ART has been studied in SIV-infected rhesus macaques
and the immunological and virologic consequences have
been investigated in peripheral blood using DNA immu-
nization [39-42], as well as other systems [43-45]. After
release from ART, variable immunologic and virologic
benefits were reported from no control [42], temporal
control [43], to long-lasting virologic control [44]. In
this study, using RhCMV immunization as a non-SIV
control in the same animal, we investigated the immu-
nologic and virologic consequences of immunization
with SIV antigen in chronic SIV and RhCMV co-
infected, ART treated rhesus macaques focusing on the
early response in draining LNs. The plasmids encoding
immunogens used for immunization were previously
demonstrated to induce potent immune responses in
uninfected macaques [19-25]. The RhCMV pp65 plas-
mid had a greater number of immunostimulatory motifs,
which would bias towards the null hypothesis. More-
over, all the comparisons between LNs at each time
point were from the same animal collected at the same
time, thus allowing us to use each animal as its own
control. Also, our study focused on the local responses
in draining LN, where the antigen-specific T cell
responses and viral replication occur, rather than sys-
temic responses in peripheral blood, as done in most
previous studies. In addition, we chose a range of days
post immunization covering the early activation of
memory T cells and generation of effector responses.
Our data show that both SIV and RhCMV antigen
immunizations induced transient immune activation and
antigen-specific T cell responses in draining LNs.
Table 1 Viral loads in periphery during antigen
immunization
Days PI* 238 290 317 336 344
Animal
CT64 < 125 < 125(D0*) < 125(D27*) < 125 < 125
DD05 < 125 < 125(D0*) < 125(D27*) < 125 < 125
FH40 < 125 < 125(D4*) 270(D31*) < 125 < 125
* Days post immunization.
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Further measurement of these responses in peripheral
blood showed that the RhCMV-specific responses were
sustained in PBMC with a rapid onset of cytokine pro-
ducing CD8+ T cells 3 days post immunization, which
was maintained at day 50-post immunization, whereas
the immunization induced SIV-specific T cell responses
were transient, appearing only on day 9 post-immuniza-
tion, and extinguished quickly in blood. The peripheral
SIV- and RhCMV-specific CD8+ T cell responses were
significantly induced compared to pre-immunization
levels, supporting that both immunizations induced
immune responses. Of interest, a study that repeatedly
immunized macaques with long-standing ART-treated
SIVmac251 infection induced stronger SIV-specific CD4
+ and CD8+ T cell responses in blood [46]. This study
used the MVA vector and delivered three immuniza-
tions, whereas in our study, only a single gag DNA
immunization was used.
HIV-specific CD4+ memory T cells are preferentially
infected by HIV, carrying approximately 2- to 5-fold
more viral DNA than total memory cells [18]. We
hypothesize that during an HIV-specific response, acti-
vation of HIV-specific CD4+ T cells, which bear higher
amounts of latent virus, results in activation of viral
replication in the LN leading to suppression of CD4+ T
cells and the HIV-specific responses through multiple
mechanisms, while a non-HIV antigen-specific response
activates less viral replication allowing more efficient
expansion of the response.
Conclusions
We used a naturally RhCMV and experimentally SIV-
mac251 co-infected and ART treated rhesus macaque
model to study the effects of immune stimulation with
SIV gag and RhCMV pp65 antigens. The study concen-
trated on the early immune and viral responses in drain-
ing lymphoid organs. Both antigen immunizations were
able to induce transient immune activation and antigen-
specific T cell responses in draining LNs, but the SIV
gag immunization also induced significant viral replica-
tion. Following immunization, the SIV response extin-
guished quickly in peripheral blood, while the RhCMV
response was sustained. Our data suggest that SIV anti-
gens, as part of the normal immune response to the
virus, leads to T cell stimulation that could potentially
lead to viral replication resulting in an impairment in
the generation of virus specific CD4+ T cells. It is possi-
ble that this mechanism is responsible for the observa-
tion that in progressing HIV-infected subjects, CD4-
specific responses to HIV antigens are lost early in
infection and are difficult to restore or induce. Further
studies are needed to determine if there is a causal link
between SIV or HIV antigen induced viral replication
and impairment of CD4+ T cell responses to the virus.
Methods
Ethics statement
All animal experiments were performed in strict accor-
dance with the standards of the Association for Assess-
ment and Accreditation of Laboratory Animal Care
International and the “Guide for the Care and Use of
Laboratory Animals” prepared by the National Research
Council. The studies were approved by the University of
Pennsylvania and Tulane Institutional Animal Care and
Use Committees.
Immunogens
Plasmid DNA expressing the SIV Gag core protein from
SIVmac239 (pSIVgag) was used. It is a Rev-independent
expression vector designed for a high level of protein
expression, as previously described [19,21-23]. Protein
expression is under the transcriptional control of the
immediate-early promoter/enhancer of human CMV
and the bovine growth hormone polyadenylation signal.
Plasmid DNA expressing the RhCMV pp65 protein
(pND/pp65-2) was used [20,24,25]. The expression of
RhCMV pp65 uses the same promoter and polyadenyla-
tion signal. The GC and CpG content of the plasmids
with inserts are: pSIVgag, 40.5% GC, no CpG-S
(GACGTT or AACGTT) motifs and 0.03 potential
CpG-N motifs (CCG, CCGG, CGG) per bp; pND-pp65,
51.3% GC, 3 CpG-S motifs and 0.0344 potential CpG-N
motifs per bp. Neither contained any human optimal
TLR9 immunostimulatory motifs (TGTCGTT). DNA
was formulated for injection in 0.15 M citrate buffer
and 0.25% bupivicaine at a pH of 6.5.
Infection of rhesus macaques and overview of study
The study timeline is shown in Figure 1. Three RhCMV
seropositive Mamu A*01 positive rhesus macaques were
intravenously infected with SIVmac251 (1000 TCID50)
at time zero. Four months after SIV infection, ART was
introduced (subcutaneous PMPA 20 mg/kg/day (Gilead
Sciences, Inc) and oral D4T 1 mg/kg/day (Bristol-
Meyers Squibb)) and continued until the end of the
experiment. The macaques were followed for 5.6
months on ART for recovery of peripheral CD4+ T cell
count and viral load suppression. Nine and a half
months after infection and 5.6 months after the initia-
tion of ART, each monkey received 2 immunizations
with SIV gag encoding DNA [19,21-23] intramuscularly
(i.m.) (2 mg/injection), one in the left arm (triceps mus-
cle) and one in the left leg (quadriceps muscle) and 2
immunizations with RhCMV pp65 encoding plasmid
[20] (2 mg/injection) in the right arm and leg. After
immunization, draining LN were sampled at two-time
points for each animal by first removing inguinal LNs
on each side followed by axillary LN removal from both
sides (Macaque FH40 - D3 and D9, Macaque DD05 -
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D5 and D11, and Macaque CT64 - D7 and D14). On
day 60 post immunization, LNs from both sides of each
animal, draining SIV gag and RhCMV pp65 immuniza-
tions, were collected. Blood was collected every 2-3
weeks throughout the experiment. PBMC were isolated
using Ficoll-diatrizoate gradient centrifugation and ana-
lyzed by flow cytometry or cryopreserved in 10%
DMSO.
Measurement of peripheral viral load and CD4+ T cell
counts
Viral RNA in plasma was quantified by a bDNA signal
amplification assay (Bayer Inc., version 4.0), specific for
SIV, which has a threshold detection limit of 125 copies
per ml of plasma [47].
CD4+ T cell counts using whole blood collected in EDTA
were analyzed with anti-CD3 (Clone SP34), anti-CD4
(Clone L200) and anti-CD8 (Clone SK1) fluorochrome-
labeled monoclonal antibodies (Beckton-Dickinson) and
white blood cell counts, as previously described [48].
LN biopsy
LN biopsy collection and processing were performed as
previously described [49]. Briefly, LNs were diced into
small pieces using scalpel blades and then pressed
through nylon mesh screens and triturated to generate
single-cell suspensions. The single cell suspensions were
divided into two parts; one was cryopreserved in 10%
DMSO and stored in liquid nitrogen and one was frozen
as a cell pellet.
In vitro stimulation
Cryopreserved LNMCs or PBMCs were thawed and re-
suspended in complete RPMI 1640 supplemented with
10% heat-inactivated serum (HyClone) and L-glutamine
(Invitrogen) and rested for two hours at 37°C. Unless
otherwise noted, cells were prepared at 1 × 106 cells/ml
for in vitro stimulation. For characterizing the SIV- and
RhCMV-specific T cell responses, LNMCs or PBMCs
were incubated with either SIVmac239 gag 15-mer pep-
tide pool with 11-amino acid overlap, 2 μg/ml each pep-
tide (NIH AIDS Research and Reference Reagent
Program) or rhesus CMV pp65 complete peptide pool
(15-mers overlapping by 11 amino acids) [20] at 2 μg/
ml for each peptide at 37°C for 6 hours in the presence
of Golgi-Stop (0.7 μg/ml), Golgi-Plug (1 μg/ml), and 1
μg/ml of co-stimulatory antibodies anti-CD28 and anti-
CD49d (BD Bioscience). Negative control with no sti-
mulation and positive control with PMA (50 ng/ml) and
Ionomycin (500 ng/ml) (Sigma-Aldrich) were used.
Cell staining and analysis
After 6 hours of stimulation, cells were washed with
washing buffer (PBS with 1% FBS, 0.09% NaN3) and
stained with aqua blue dye (Invitrogen) and pre-titrated
amounts of fluorochrome-conjugated surface staining
antibodies (anti-CD4-PerCP Cy5.5, anti-CD8-FITC, anti-
CD14-Pac Blue, anti-CD16-Pac Blue, anti-CD95-PE-Cy5,
anti-CD20-Pac Blue (eBioscience), and anti-CD28-ECD
(Beckman Coulter) and incubated at 4°C for 20 minutes.
Cells were then washed and fixed in 250 μl BD Fixa-
tion/Permeabilization solution (BD Biosciences) for 20
minutes at 4°C. After fixation, cells were permeabilized
with 1 × BD Perm/Wash buffer and stained with pre-
titrated fluorochrome-conjugated antibodies (anti-CD3-
APC-Cy7, anti-IL-2-PE, anti-IFN-g-APC, and anti-TNF-
a-PE-Cy7 (BD Biosciences) at 4°C for 45 minutes. Cells
were then washed with Perm/Wash buffer and re-sus-
pended in 300 μl PBS, 1% FBS.
Cells were analyzed on an LSR-II flow cytometer (BD
Biosciences) equipped for the detection of 18 fluores-
cence parameters and 200,000 to 500,000 events were
obtained. Flow Jo version 8.8.7. (Tree Star) was used to
analyze the polychromatic flow data with the analytic
gating performed as described [50,51].
Tetramer analyses
PBMCs were stained with aqua blue; CD14-, CD16-, and
CD20-pacific blue; CD3-Cy7-APC; CD8-FITC; and p11C
(CTPYDINQM) tetramer-APC (Beckman Coulter) and
analyzed on an LSR II flow cytometer.
Quantitative PCR
Total RNA from LNMCs was isolated using Trizol
according to manufacturer’s instruction (Invitrogen)
and subject to real-time (RT)-PCR on an ABI 7500
(Applied Biosystem). Doubly spliced (Tat), singly
spliced (Vif), and unspliced (Gag) SIV RNA and the
housekeeping gene GAPDH were analyzed. The pri-
mers and MGB probes for these genes were obtained
from Applied Biosystems (Table 2). Changes in the
expression of individual viral RNAs with GAPDH nor-
malization were calculated utilizing delta cycle thresh-
old (ΔCT) values.
Levels of IFN-g mRNA were quantitated by RT-PCR
against a standard curve derived from serial dilutions of
in vitro made transcripts using specific primers and
probe (Table 2). Copies of IFN-g mRNA were expressed
as per 1 μg of total RNA.
Statistics
Mean, standard error of the mean, and student’s t-test
were performed using Microsoft Excel software. For the
comparison of viral RNA in LNs draining SIV and
RhCMV antigen immunization sites on the same day
from the same animal, random effects models were used
to adjust for the inherent correction between observa-
tions from the same animal. Relative changes were log-
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transformed for analyses in order to meet normality
assumptions. SAS 9.2 was used for the analyses.
Acknowledgements and Funding
We thank Sarah Ratcliffe (University of Pennsylvania) for assistance with the
statistical analyses. These studies were supported by a Pilot grant from the
University of Pennsylvania Center for AIDS Research, a Public Health Service
grant AI-050484 from the National Institute of Allergy and Infectious
Diseases, and by the base operating grant to the Tulane National Primate
Research Center P51-000164.
Author details
1Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA,
USA. 2Department of Molecular and Comparative Pathobiology, Johns
Hopkins University School of Medicine, Baltimore, MD, USA. 3Tulane National
Primate Research Center, Covington, LA, USA. 4Center for Comparative
Medicine, University of California-Davis, Davis, CA, USA.
Authors’ contributions
HH performed the immunologic and virologic analyses and drafted the
manuscript. LG performed immunologic analyses. PPA and AAL performed
all animal manipulations and experimentation. JEC and PAB participated in
its design and coordination. DW conceived of the study, participated in its
design and coordination, and helped to draft the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 April 2011 Accepted: 13 July 2011 Published: 13 July 2011
References
1. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA,
Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with
control of viremia. Science 1997, 278:1447-1450.
2. Wilson JDK, Imami N, Watkins A, Gill J, Hay P, Gazzard B, Westby M,
Gotch FM: Loss of CD4+ T cell proliferative ability but not loss of human
immunodeficiency virus type 1 specificity equates with progression to
disease. J Infect Dis 2000, 182:792-798.
3. Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, Klenerman P,
Walker BD: Detection of polyfunctional mycobacterium tuberculosis-
specific T cells and association with viral load in HIV-1-infected persons.
J Infect Dis 2008, 197:990-999.
4. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS:
Qualitative-analysis of immune function in patients with the acquired
immunodeficiency syndrome - evidence for a selective defect in
soluble-antigen recognition. New Engl J Med 1985, 313:79-84.
5. Miedema F, Petit AJC, Terpstra FG, Schattenkerk J, Dewolf F, Al BJM,
Roos M, Lange JMA, Danner SA, Goudsmit J, Schellekens PTA:
Immunological abnormalities in human immunodeficiency virus (HIV)-
infected asymptomatic homosexual men - HIV affects the immune-
system before CD4+ T-helper cell depletion occurs. J Clin Invest 1988,
82:1908-1914.
6. Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K,
Heeregrave EJ, Casazza JP, Ambrozak DR, Louder M, Ampofo W, Pollakis G,
Hill B, Sanga E, Saathoff E, Maboko L, Roederer M, Paxton W, Hoelscher M,
Koup RA: Preferential infection and depletion of mycobacterium
tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010,
207:2869-2881.
7. Cao H, Walker BD: Immunopathogenesis of HIV-1 infection. Clin Dermatol
2000, 18:401-410.
8. Elrefaei M, McElroy MD, Preas CP, Hoh R, Deeks S, Martin J, Cao HY: Central
memory CD4(+) T cell responses in chronic HIV infection are not
restored by antiretroviral therapy. J Immunol 2004, 173:2184-2189.
9. Krowka JF, Stites DP, Jain S, Steimer KS, Georgenascimento C, Gyenes A,
Barr PJ, Hollander H, Moss AR, Homsy JM, Levy JA, Abrams DI: Lymphocyte
proliferative responses to human immunodeficiency virus-antigens in
vitro. J Clin Invest 1989, 83:1198-1203.
10. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M,
Kotzin BL, Fox L, Chiozzi H, Leonard JM, Rousseau F, Wade M, Roe JD,
Martinez A, Kessler H: Immunologic responses associated with 12 weeks
of combination antiretroviral therapy consisting of zidovudine,
lamivudine, and ritonavir: Results of aids clinical trials group protocol
315. J Infect Dis 1998, 178:70-79.
11. Wahren B, Morfeldtmansson L, Biberfeld G, Moberg L, Sonnerborg A,
Ljungman P, Werner A, Kurth R, Gallo R, Bolognesi D: Characteristics of the
specific cell-mediated immune-response in human immunodeficiency
virus-infection. J Virol 1987, 61:2017-2023.
12. Gudmundsdotter L, Sjodin A, Bostrom AC, Hejdeman B, Theve-Palm R,
Alaeus A, Lidman K, Wahren B: Therapeutic immunization for HIV. Springer
Semin Immunopathol 2006, 28:221-230.
13. Wu L, KewalRamani VN: Dendritic-cell interactions with HIV: Infection and
viral dissemination. Nature Rev Immunol 2006, 6:859-868.
14. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS,
Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM: Virologic and
immunologic consequences of discontinuing combination antiretroviral-
drug therapy in HIV-infected patients with detectable viremia. N Engl J
Med 2001, 344:472-480.
15. Persaud D, Siberry GK, Ahonkhai A, Kajdas J, Monie D, Hutton N,
Watson DC, Quinn TC, Ray SC, Siliciano RF: Continued production of drug-
sensitive human immunodeficiency virus type 1 in children on
combination antiretroviral therapy who have undetectable viral loads. J
Virol 2004, 78:968-979.
16. Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D’Aquila RT,
Quinn TC, Siliciano JD, Siliciano RF, Persaud D: HIV-1 drug resistance
profiles in children and adults with viral load of <50 copies/ml receiving
combination therapy. JAMA 2001, 286:196-207.
17. Pierson T, McArthur J, Siliciano RF: Reservoirs for HIV-1: Mechanisms for
viral persistence in the presence of antiviral immune responses and
antiretroviral therapy. Annu Rev Immunol 2000, 18:665-708.
18. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y,
Casazza JP, Kuruppu J, Kuntsman K, Wolinsky S, Grossman Z, Dybul M,
Oxenius A, Price DA, Connors M, Koup RA: HIV preferentially infects HIV-
specific CD4(+) T cells. Nature 2002, 417:95-98.
19. Boyer JD, Robinson TM, Maciag PC, Peng X, Johnson RS, Pavlakis G,
Lewis MG, Shen A, Siliciano R, Brown CR, Weiner D, Paterson Y: DNA prime
listeria boost induces a cellular immune response to SIV antigens in the
rhesus macaque model that is capable of limited suppression of SIV239
viral replication. Virology 2005, 333:88-101.
20. Yue Y, Kaur A, Eberhardt MK, Kassis N, Zhou SS, Tarantal AF, Barry PA:
Immunogenicity and protective efficacy of DNA vaccines expressing
rhesus cytomegalovirus glycoprotein b, phosphoprotein 65-2, and viral
interleukin-10 in rhesus macaques. J Virol 2007, 81:1095-1109.
21. Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R,
Israel Z, Montefiori DC, Ugen K, Miller N, Kim J, Boyer J, Weiner DB: A Gag-
Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral
Table 2 Primers and probes for real-time PCR
SIV doubly spliced Forward: 5’- AGGCTAATACATCTTCTGCATCAAAC - 3’
Reverse: 5’- GGGTCCTGTTGGGTATGAGTCTA - 3’
Probe: 5’ - CCACCCTCTTATTTCC - 3’
SIV singly spliced Forward: 5’- AGAGGCCTCCGGTTGCA-3’
Reverse: 5’- CCTTCCCCTTTCCACAATAGC-3’
Probe: 5’-ACTGTGGAAGGGACC-3’
SIV unspliced Forward: 5’- TTGCAGCACCCACAACCA-3’
Reverse: 5’-TGATCCTGACGGCTCCCTAA-3’
Probe: 5’- CTCCACAACAAGGACA-3’





Probe: 5’- AGGTGGTCTCCTCTGAC -3’
Hu et al. Retrovirology 2011, 8:57
http://www.retrovirology.com/content/8/1/57
Page 10 of 11
loads after pathogenic intrarectal SIVmac251 challenge in rhesus
macaques. Vaccine 2003, 21:629-637.
22. Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, Sidhu MK,
Muthumani K, Lewis M, Pavlakis G, Felber B, Weiner D: SIV DNA vaccine co-
administered with IL-12 expression plasmid enhances CD8 SIV cellular
immune responses in cynomolgus macaques. J Med Primatol 2005,
34:262-270.
23. Schadeck EB, Sidhu M, Egan MA, Chong S-Y, Piacente P, Masood A, Garcia-
Hand D, Cappello S, Roopchand V, Megati S, Quiroz J, Boyer JD, Felber B,
Pavlakis G, Weiner DB, Eldridge JH, Israel ZR: A dose sparing effect by
plasmid encoded IL-12 adjuvant on a SIV gag-plasmid DNA vaccine in
rhesus macaques. Vaccine 2006, 24:4677-4687.
24. Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, Strelow L, Dasgupta A, Li Z,
Schmidt KA, Oxford KL, Assaf B, Longmate JA, Diamond DJ, Barry PA:
Vaccine-induced control of viral shedding following rhesus
cytomegalovirus challenge in rhesus macaques. J Virol 2011,
85:2878-2890.
25. Abel K, Strelow L, Yue Y, Eberhardt MK, Schmidt KA, Barry PA: A
heterologous DNA prime/protein boost immunization strategy for
rhesus cytomegalovirus. Vaccine 2008, 26:6013-6025.
26. Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant RM, Lerche N,
Feinberg MB: Simian immunodeficiency virus disease course is predicted
by the extent of virus replication during primary infection. J Virol 1999,
73:4829-4839.
27. Harrington PR, Connell MJ, Meeker RB, Johnson PR, Swanstrom R: Dynamics
of simian immunodeficiency virus populations in blood and
cerebrospinal fluid over the full course of infection. J Infect Dis 2007,
196:1058-1067.
28. Park IW, Steen R, Li Y: Characterization of multiple mRNA species of
simian immunodeficiency virus from macaques in a CD4+ lymphoid cell
line. J Virol 1991, 65:2987-2992.
29. Douek DC, Picker LJ, Koup RA: T cell dynamics in HIV-1 infection. Annu
Rev Immunol 2003, 21:265-304.
30. Picker LJ, Watkins DI: HIV pathogenesis: The first cut is the deepest. Nat
Immunol 2005, 6:430-432.
31. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C,
Debre P, Leibowitch J: Positive effects of combined antiretroviral therapy
on CD4+ T cell homeostasis and function in advanced HIV disease.
Science 1997, 277:112-116.
32. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune
response of human immunodeficiency virus (HIV)-infected subjects
treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996,
173:321-329.
33. Rinaldo CR Jr, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK,
Day RD, Riddler SA, Mellors JW: Prolonged suppression of human
immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced
disease results in enhancement of CD4 T cell reactivity to microbial
antigens but not to HIV-1 antigens. J Infect Dis 1999, 179:329-336.
34. Letvin NL: Animal-models for AIDS. Immunol Today 1990, 11:322-326.
35. Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N,
Williams J, Kinter A, Fauci AS, Hirsch VM, Lifson JD: Viral dynamics of
primary viremia and antiretroviral therapy in simian immunodeficiency
virus infection. J Virol 1997, 71:7518-7525.
36. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, Moorman AC,
Holmberg SD, Investigators at HOS: Prevalence and clinical correlates of
HIV viremia (’blips’) in patients with previous suppression below the
limits of quantification. AIDS 2002, 16:2035-2041.
37. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B,
Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A,
Kearney M, Coffin JM, Mellors JW, Eron JJ: AIDS Clinical Trial A5244 Team:
The effect of raltegravir intensification on low-level residual viremia in
HIV-infected patients on antiretroviral therapy: A randomized controlled
trial. PLoS Med 2010, 7:e1000321.
38. Papasavvas E, Kostman J, Thiel B, Pistilli M, Mackiewicz A, Foulkes A, Gross R,
Jordan K, Nixon D, Grant R, Poulin JF, McCune J, Mounzer K, Montaner L:
HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected
blippers on antiretroviral therapy in relation to viral replication following
treatment interruption. J Clin Immunol 2006, 26:40-54.
39. Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C,
Jalah R, Patel V, Khan AS, Draghia-Akli R, Pavlakis GN, Felber BK: Repeated
DNA therapeutic vaccination of chronically SIV-infected macaques
provides additional virological benefit. Vaccine 2010, 28:1962-1974.
40. Fuller DH, Rajakumar PA, Wu MS, McMahon CW, Shipley T, Fuller JT,
Bazmi A, Trichel AM, Allen TM, Mothe B, Haynes JR, Watkins DI, Murphey-
Corb M: DNA immunization in combination with effective antiretroviral
drug therapy controls viral rebound and prevents simian AIDS after
treatment is discontinued. Virology 2006, 348:200-215.
41. von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G,
Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR,
Eldridge JH, Pavlakis GN, Felber BK: Long-lasting decrease in viremia in
macaques chronically infected with simian immunodeficiency virus
SIVmac251 after therapeutic DNA immunization. J Virol 2007,
81:1972-1979.
42. zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A,
Hebblewaite D, Sites D, Nieves- Duran L, Srivastava R, Otten GR, Rabussay D,
Zhang L, Ulmer JB, Barnett SW, Donnelly JJ: A therapeutic SIV DNA
vaccine elicits T-cell immune responses, but no sustained control of
viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retrov
2008, 24:1103-1116.
43. Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, Chougnet C,
Shearer G, Altman JD, Watkins D, Bischofberger N, Abimiku A, Markham P,
Tartaglia J, Franchini G: Viremia control following antiretroviral treatment
and therapeutic immunization during primary SIV251 infection of
macaques. Nat Med 2000, 6:1140-1146.
44. Lu W, Wu XX, Lu YZ, Guo WZ, Andrieu JM: Therapeutic dendritic-cell
vaccine for simian AIDS. Nat Med 2003, 9:27-32.
45. De Rose R, Fernandez CS, Smith MZ, Batten CJ, Alcantara S, Peut V,
Rollman E, Loh L, Mason RD, Wilson K, Law MG, Handley AJ, Kent SJ:
Control of viremia and prevention of AIDS following immunotherapy of
SIV-infected macaques with peptide-pulsed blood. Plos Pathogens 2008,
4.
46. Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z,
Parks RW, Moniuszko M, Tartaglia J, Smith KA, Franchini G: Vaccination of
macaques with long-standing SIVmac251 infection lowers the viral set
point after cessation of antiretroviral therapy. J Immunol 2002,
169:5347-5357.
47. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M, Kunstman K,
Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I,
Wolinsky SM, Doms RW, Demartino JA, Siciliano SJ, Lyons K, Springer MS,
Moore JP: Use of a small molecule ccr5 inhibitor in macaques to treat
simian immunodeficiency virus infection or prevent simian-human
immunodeficiency virus infection. J Exp Med 2003, 198:1551-1562.
48. Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, Gettie A,
Fenamore EA, Sheridan KE, Ho DD, Dailey PJ, Marx PA: Temporal analyses
of virus replication, immune responses, and efficacy in rhesus macaques
immunized with a live, attenuated simian immunodeficiency virus
vaccine. J Virol 1998, 72:7501-7509.
49. Veazey RS, Tham IC, Mansfield KG, DeMaria M, Forand AE, Shvetz DE,
Chalifoux LV, Sehgal PK, Lackner AA: Identifying the target cell in primary
simian immunodeficiency virus (SIV) infection: Highly activated memory
CD4+ T cells are rapidly eliminated in early SIV infection in vivo. J Virol
2000, 74:57-64.
50. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J,
Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA:
HIV nonprogressors preferentially maintain highly functional HIV-specific
CD8(+) T cells. Blood 2006, 107:4781-4789.
51. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ,
Roederer M, Douek DC, Koup RA: Acquisition of direct antiviral effector
functions by CMV-specific CD4(+) T lymphocytes with cellular
maturation. J Exp Med 2006, 203:2865-2877.
doi:10.1186/1742-4690-8-57
Cite this article as: Hu et al.: SIV antigen immunization induces
transient antigen-specific T cell responses and selectively activates viral
replication in draining lymph nodes in retroviral suppressed rhesus
macaques. Retrovirology 2011 8:57.
Hu et al. Retrovirology 2011, 8:57
http://www.retrovirology.com/content/8/1/57
Page 11 of 11
